Gene-based strategies for the immunotherapy of cancer

Journal of Molecular Medicine

Volumn 75, Issue 7, 1997, Pages 478-491

  Tüting, Thomas ^a   Storkus, Walter J ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Dendritic cell; Gene therapy; Immunotherapy

Indexed keywords

MELANOMA ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; GENE TARGETING; GENE TECHNOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030875460     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050133     Document Type: Review

References (142)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
2. Boon T, Van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
3. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meleon RH, van der Eb AJ, Melief CJM (1989) Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59:603-614
4. Melief CJM (1991) Tumor eradication by adoptive transfer of of cytotoxic lymphocytes. Adv Cancer Res 58:143-175
5. Rosenberg SA, Spiess P, Lafreniere RA (1986) A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science 233:1318-1321
6. Rosenberg SA, Pacard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp C, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680
7. Kawakami Y, Eliyahu J, Delgado CH, Robbins PF, Sakaguchi K, Apella E, Yanelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:3515-3519
8. Kirkwood JM, Ernstoff MS (1984) Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol 13:48-56
9. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High dose recombinant interleukin-2 in the treatmenht of patients with disseminated cancer: Responses, tretment related morbidity and histologie findings. JAMA 256: 3117-3124
10. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SE (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169-1188
11. Rosenberg SA, Eotze MT, Muul E, Chang AE, Avis FP, Eeitman S, Einehan WM, Robertson CN, Eee RE, Rubin JT, Seipp CA, Simpson CG White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889897
12. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276
13. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J ExpMed 178:1223-1230
14. Nastala CL, Edington H, Storkus WJ, McKinney TG, Tahara H, Brunda MJ, Gately MK, Schreiber RD, Lotze MT (1994) Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production. J Immunol 146:1697-1706
15. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato E, Tahara H, Sherman ME (1997) Phase I evaluation of intravenous recombinant human interleukin-12 (rhIE-12) in patients with advanced malignancies. Clin Cancer Res (in press)
16. Foley EJ (1953) Antigenic properties of methylcholanthreneinduced tumors in mice of the strain of origin. Cancer Res 13: 835-837
17. Prehn RT, Main JM (1957) Immunity to methylcholanthreneinduced sarcomas. J Natl Cancer Inst 18:769-778
18. Knuth A, Dnowski B, Oettgen HF, Old E (1984) T-cell mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2-dependent T-cell cultures. Proc Natl Acad Sci USA 81:3511-3515
19. Herin M, Eemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T cell clones directed against autologous human melanoma. Int J Cancer 39:390-396
20. Strohal R, Marberger K, Pehamberger H, Stingl G (1994) Immunohistological analysis of anti-melanoma host responses. Arch Dermatol Res 287:28-35
21. Topalian SE, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanoma. J Immunol 142:3714-3725
22. Mackenson A, Carcelain G, Viel S, Raynal S, Michalaki H, Triebel F, Bosq J, Hercend T (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93:1397-1402
23. Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274-278
24. Kawakami Y, Zakut R, Topalian SE, Stotter M, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HEA-A2.1 transfected melanoma. J Immunol 148:638-646
25. Slingluff CE, Cox AE, Henderson RA, Hunt DF, Engelhard VH (1993) Recognition of human melanoma cells by HEAA2.1-restricted cytotoxic lymphocytes is mediatied by at least six shared peptide epitopes. J Immunol 150:29552961
26. Bernhard H, Maurer MJ, Jäger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WJ, Eotze MT, Meyer zum Büschenfelde K-H, Knuth A (1996) Recognition of human renal cell carcinoma and melanoma by HEA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and upregulated by interferon-γ. Scand J Immunol 44:285-292
27. Bubenik J, Voitenok NN, Kieler J (1988) Eocal administration of cells containing an inserted IE-2 gene and producing IE-2 inhibits growth of human tumors in nu/nu mice. Immunol Eett 19:279-282
28. Bubenik J, Simova J, Jandlova T (1988) Immunotherapy of cancer using local administration of lymphoid cells transformed by IE-2 cDNA and constitutively producing IE-2. Immunol Eett 23:287-292
29. Fearon E, Pardoll D, Itaya T, Golumbek P, Eevitsky H, Simons J, Karasayama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-4Q3
30. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
31. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin4 displays potent antitumor activity in vivo. Cell 57: 503-512
32. Golumbek P, Lazenby A, Levitsky H, Jaffee L, Karasuyama H, Baker M, Paroll DM (1991) Treatment of established renal cancer by tymor cells engineered to secrete interleukin-4. Science 254:713-716
33. Tepper RI (1992) The tumor-cytokine transplantation assay and the antitumor activity of interleukin-4. Bone Marrow Transpl 9 [Suppl 1]:177-181
34. Tepper RI, Mule JJ (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Ther 5: 153-164
35. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415
36. Forni G, Cavallo F, Consalvo M, Allione A, Dellabonna P, Casorati G, Giovarelli M (1995) Molecular approaches to cancer immunotherapy. Cytokines Mol Ther 1:225-248
37. Parmiani G, Colombo MP, Melani C, Arienti F (1997) Cytokine gene-transduction in the immunotherapy of cancer. Adv Pharmacol (in press)
38. Dranoff G, Jaffee L, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hirofumi H, Paroll DM, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting antitumor immunity. Proc Natl Acad Sci USA 90: 3539-3543
39. Hock H, Dorsch M, Kunzendorf U, Überia K, Quin Z, Diamantstein T, Blankenstein T (1993) Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53:714-716
40. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kämpgen E, Romani N, Schuler G (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184:741-746
41. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747-752
42. Nastala CL, Edington H, Storkus WJ, McKinney TG, Tahara H, Brunda MJ, Gately MK, Schreiber R, Lotze MT (1994) Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production. J Immunol 146:1697-1706
43. Tahara H, Zeh HJ, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT (1994). Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189
44. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466-6474
45. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clark MR, Nalesnik M, Gately MK, Lotze MT (1995) Cancer immunotherapy of established tumors with Interleukin-12 (IL-12): effective delivery by genetically engineered fibroblasts. J Immunol 155:1393-1403
46. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L (1995) Clinical protocol: IL-12 gene therapy using direct injections of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 6:1607-1624
47. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Wolf SF, Gately M, Lotze MT (1994) Construction and characterization of retroviral vectors expressing biologically active human Interleukin 12 (IL-12). Hum Gene Ther 5:1493-1506
48. Elder EM, Lotze MT, Whiteside TL (1996) Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biological therapy of patients with cancer. Hum Gene Ther 7:479-487
49. Ferbas J, Toso JF, Logar AJ, Navratil JS, Rinaldo CR (1994) CD4+ blood dendritic cells are potent producers of IFN-α in response to in vitro HIV-1 infection. J Immunol 152: 4649-4662
50. Fitzgerald-Bocarsly P (1993) Human natural interferon-α producing cells. Pharmac Ther 60:39-62
51. Eloranta M-L, Sandberg K, Alm GV (1996) The interferonα/bresponses of mice to herpes simplex virus studied at the blood and tissue level in vitro and in vivo. Scand J Immunol 43:355-360
52. Svensson H, Johanisson A, Nikkila T, Alm GV, Cederblad B (1996) The cell surface phenotype of human natural interferon a producing cells as determined by flow cytometry. Scand J Immunol 44:164-172
53. Belardelli F, Gresser I (1996) The neglected role of type I interferon in T-cell response: implications for its clinical use. Immunol Today 17:369-372
54. Tough DF, Borrow P, Sprent J (1996) Induction of bystander T cell proliferation by viruses and type I Interferon in vivo. Science 272:1947-1950
55. Belardelli F (1995) Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161-179
56. Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Eollini P-L, Nanni P, Forni G, Belardelli F (1994) IFN-alpha 1 gene expression into metastatic murine adenocarcinoma (TS/A) results in CD8+T cellmediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma producing TS/A cells. J Immunol 153:4604-4615
57. Arienti F, Sulé-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G (1996) Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7:1955-1963
58. Leimig T, Brenner M, Ramsey J, Vanin E, Blaese M, Dilloo D (1996) High-efficiency transduction of freshly isolated human tumor cells using adenviral interleukin-2 vectors. Hum Gene Ther 7:1233-1239
59. Zhang JF, Hu C, Geng Y, Selm J, Klein SB, Orazi A, Taylor M W (1996) Treatment of a human breast cancer xenograft with an adenovirus vector containing an Interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA 93:4513-4518
60. Zhang JF, Hu C, Geng Y, Blatt LM, Taylor MW (1996) Gene therapy with an adeno-associated virus carrying an Interferon gene results in tumor growth suppression and regression. C ancer Gene Ther 3:31-38
61. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A, Glaspy J, Economou JS (1996) In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 3:11-17
62. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL (1996) Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and longlasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7:1995-2002
63. Meko JB, Yim JH, Tsung K, Norton JA (1995) High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 55: 4765-4770
64. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobrt P, Norman J, Manthorpe M (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7:1205-1217
65. Felgner PL (1996) Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther 7:1791-1793
66. Parker SE, Khatibi S, Margalith M, Anderson D, Yankauckas M, Gromkowski SH, Latimer T, Lew D, Marquet M, Manthorpe M, Hobart P, Hersh E, Stopeck AT, Norman J (1996) Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 3:175-185
67. Yang N-S, Burkholder JK, Roberts B, Martinell B, McCabe D (1990) In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 87: 9568-9572
68. Yang N-S, Sun WH (1995) Gene gun and other non-viral approaches for cancer gene therapy. Nat Med 1:481-483
69. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grata K, Yang N-S (1996) Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291-6296
70. Mahvi DM, Burkholder JK, Shi F, Pugh TD, McCabe D, Malter JS, MacEwen EG, Yang N-S, Ershler WB (1996) Particle-mediated gene transfer of Granulocyte-MacrophageColony-Stimulating Factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Human Gene Ther 7: 1535-1543
71. Albertini MR, Emler CA, Schell K, Tans KJ, King DM, Sheehz MJ (1996) Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. Cancer Gene Ther 3:192-201
72. Schadendorf D, Czarnetzki BM, Wittig B (1995) Interleukin7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 73:473-477
73. Cristiano RJ, Roth JA (1995) Molecular conjugates: a targeted gene delivery vector for molecular medicine. J Mol Med 73:479-486
74. Zatloukal JM, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Apayer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 154:3406-3419
75. Harris JD, Lemoine NR (1996) Strategies for targeted gene therapy. Trends Genet 12:400-405
76. Wilson M (1996) A pharmacological rheostat for gene therapy. Nat Med 2:977-978
77. Townsend A, Bodmer H (1989) Antigen recognition by class I restricted T lymphocytes. Annu Rev Immunol 7:601-624
78. Cresswell P (1993) Antigen processing. Annu Rev Immunol 11:259-293
79. Engelhard VH (1994) Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12: 181-207
80. Storkus WJ, Lotze MT (1995) Tumor antigens recognized by immune cells. In: DeVita VT, Hellmann S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 64-77
81. Rammensee HG (1995) Chemistry of peptides associated with MHC class I and II molecules. Curr Opin Immunol 7: 85-96
82. Falk K, Rotzschke O (1993) Consensus motifs and peptide ligands of MHC class I molecules. Semin Immunol 5:81-89
83. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM (1996) Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:431-437
84. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153: 5586-5592
85. Van der Burg AH, Visseren MJW, Brandt RMP, Kast WM, Melief CJM (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156:3308-3314
86. Van Elsas A, van der Berg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJM, Schrier PI (1996) Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HEA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J Immunol 26: 1683-1689
87. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
88. Van den Eynde B, Brichard VG (1995) New tumor antigens recognized by T cells. Curr Opin Immunol 7:674-68
89. Boon T, Van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
90. Van der Bruggen P, Traversari PC, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
91. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HEA-A2 melanomas. J Exp Med 178:489-495
92. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J-P, Renauld JC, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HEA-A2 melanomas. J Exp Med 180:35-42
93. Traversari C, van der Bruggen P, Lüscher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HEA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457
94. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde K-H, Boon T (1994) Two tyrosinase nonapeptides recognized on HEA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24: 759-764
95. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Schabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719
96. Castelli C, Storkus WJ, Mäurer MJ, Martin D, Huang EC, Pramanik BN, Nagabhushan TE, Lotze MT (1995) Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 181:363-368
97. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabinowitz J, Wölfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HEA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183: 527-534
98. Celis E, Tsai V, Crimi C, DeMars T, Wentworth PA, Chesnut TW, Grey HM, Sette A, Serra HM (1994) Induction of antitumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109
99. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJM (1993) In vitro induction of human cytotoxic T lymphocyte resopnses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072-2077
100. Noguchi Y, Chen Y-T, Old E (1994) A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 91:3171-3175
101. Lacabann V, Viguier M, Guillet J-G, Choppin J (1996) A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 26:2635-2639
102. Theobald M, Biggs J, Dittmer D, Levine A, Sherman L (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993-11997
103. Röpke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Sveigard A, van der Burg S, Nijman HW, Melief CJM, Claesson MH (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 93:14704-14707
104. Disis ML, Cheever MA (1996) Oncogenic proteins as tumor antigens. Curr Opin Immunol 8:637-642
105. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartmann M, Oseroff C, Grey HM, Melief CJM, Käst WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HEA-A*0201-binding peptides. J Immunol 154:5934-5943
106. Tindle RW (1996) Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 8:643-650
107. Ertl HCJ, Xiang Z (1996) Novel vaccine approaches. J Immunol 156:3579-3582
108. Ulmer JB, Sadoff JC, Liu MA (1996) DNA vaccines. Curr Opin Immunol 8:531-536
109. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP (1995) Active immunotherapy of cancer with a nonrepliating recombinant fowl poxvirus encoding a model tumor-associated antigen. J Immunol 154:4685-4692
110. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP (1995) IE-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154:5282-5292
111. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156:224-231
112. Warnier G, Duffour M-T, Uyttenhove C, Gajewski T, Lurquin C, Haddada H, Perricaudet M, Boon T (1996) Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer 67: 303-310
113. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA (1996) Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 156:700-710
114. Irvine KR, Rao RB, Rosenberg SA, Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238-245
115. Conry RM, Widera G, LoBuglio AF, Fuller JT, Moore ST, Barlow DL, Turner J, Yang N-S, Curiel DT (1996) Selected strategies to augment polynucleotide immunization. Gene Ther 3:67-74
116. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo ED (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122-1128
117. Ulmer JB, Deck RR, Dewitt CM, Donnelly JJ Liu MA (1996) Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunol 89:59-67
118. Corr M, Lee DJ, Carson DA, Tighe H (1996) Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555-1560
119. Huang AYC, Golumbek P, Ahamadzadeh M, Jaffee E, Pardoll DM, Levitsky HI (1994) The role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
120. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen M-D, Silverman GJ, Lotz M, Carson DA, Raz E (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354
121. Stacey KJ, Sweet MJ Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157: 2116-2122
122. Pisetzki DS (1996) Immune activation by bacterial DNA: a new genetic code. Immunity 5:303-310
123. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
124. Stingl G, Bergstresser PR (1995) Dendritic cells: a major story unfolds. Immunol. Today 16:330-333
125. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony-stimulating factor. J Exp Med 176:1693-1702
126. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Gritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
127. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor-immunity. J Exp Med 183:7-11
128. Mayordomo JI, Zorina T, Storkus WJ, Celuzzi CM, Falo LD, Käst WM, Ildstad ST, DeLeo AB, Lotze MT (1995) Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat Med 1:1297-1302
129. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare SM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357-1365
130. Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918-2926
131. Bakker ABH, Marland G, de Boer AJ, Huijbens JE, Danen EHJ, Adema GJ, Figdor DG (1995) Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:5330-5334
132. Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D (1995) Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 25:3100-3107
133. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ (1996) Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56:3763-3770
134. Reeves ME, Royal RE, Earn JS, Rosenberg SA, Hwu P (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56:5672-5677
135. Boczkowski D, Nair, SK, Snyder D, Gilboa E (1996) Dendritic Cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
136. Ciernik IF, Berzofsky JA, Carbone D (1996) Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156: 2369-2375
137. Lin K-Y, Guarnieri FG, Staveley-O'Caroll KF, Eevitsky HI, August JT, Pardoll DM, Wu T-C (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26
138. Mäurer MJ, Storkus WJ, Kirkwood JM, Lotze MT (1996) New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24
139. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366
140. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) lymphocyte apoptosis induced by CD95 (APO-I/Fas) ligandexpressing tumor cells - a mechanism of immune evasion? Nat Med 2:1361-1366
141. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082
142. Seino K-I, Kayagaki N, Okumura K, Yagita H (1997) Antitumor effect of locally produced CD95 ligand. Nat Med 3: 165-170